Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?

IF 3.5 Q2 ONCOLOGY
J. Humberto Rodriguez-Quintero MD, MPH , Rajika Jindani MD, MPH, MS , Roger Zhu MD , Isaac Loh , Mohamed K. Kamel MD , Anne Montal MD , Marc Vimolratana MD, MS , Neel P. Chudgar MD , Nitin Ohri MD, MS , Balazs Halmos MD, MS , Brendon M. Stiles MD
{"title":"Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?","authors":"J. Humberto Rodriguez-Quintero MD, MPH ,&nbsp;Rajika Jindani MD, MPH, MS ,&nbsp;Roger Zhu MD ,&nbsp;Isaac Loh ,&nbsp;Mohamed K. Kamel MD ,&nbsp;Anne Montal MD ,&nbsp;Marc Vimolratana MD, MS ,&nbsp;Neel P. Chudgar MD ,&nbsp;Nitin Ohri MD, MS ,&nbsp;Balazs Halmos MD, MS ,&nbsp;Brendon M. Stiles MD","doi":"10.1016/j.jtocrr.2024.100766","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Chemoradiation followed by durvalumab is considered a standard approach for patients with locally advanced NSCLC. With improvements in perioperative and neoadjuvant approaches, there is renewed interest in offering surgery to carefully selected patients with cT3/4N2 stage IIIB cancer. We sought to assess survival outcomes after surgery as part of a multimodality treatment regimen for these patients.</div></div><div><h3>Methods</h3><div>Patients with cT3/T4N2M0 NSCLC who received surgery (S) as part of a multimodality approach and patients receiving multimodality treatment without surgery (chemoradiation [CRT] or systemic therapy only) were identified in the National Cancer Database (2010–2019). We evaluated factors associated with the receipt of S (logistic regression). After propensity matching, we estimated the overall survival (OS) of patients who received S and compared with those who received CRT (Kaplan-Meier and Cox regression).</div></div><div><h3>Results</h3><div>A total of 44,756 patients were identified, of whom 3928 (8.8%) underwent S, 29,798 (66.6%) CRT, and 11,030 (24.6%) systemic therapy only. Fewer comorbidities (Charlson-Deyo index 0 or 1, adjusted OR [aOR]: 1.22, 95% confidence interval [CI]: 1.05–1.42), treatment at an academic facility (aOR: 1.70, 95% CI: 1.52–1.89), private insurance (aOR: 2.44, 95% CI: 1.61–3.69), adenocarcinoma histology (aOR: 1.48, 95% CI: 1.22–1.79), and clinical T3 stage (&lt;7 cm, aOR: 1.70, 95% CI: 1.53–1.89) were associated with S. In well-balanced, propensity-matched cohorts, patients selected for S had better OS compared with those who underwent CRT (hazard ratio 0.59, 95% CI: 0.56–0.63, <em>p</em> &lt; 0.001) (median OS 49.7 versus 25.0 mo).</div></div><div><h3>Conclusions</h3><div>In this retrospective cohort analysis, patients with cT3/4N2, stage IIIB NSCLC who underwent surgical resection had better OS compared with those patients treated with CRT. Careful patient selection is undoubtedly critical, but stage IIIB designation alone should not exclude patients from surgical consideration.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 1","pages":"Article 100766"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699383/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266636432400136X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Chemoradiation followed by durvalumab is considered a standard approach for patients with locally advanced NSCLC. With improvements in perioperative and neoadjuvant approaches, there is renewed interest in offering surgery to carefully selected patients with cT3/4N2 stage IIIB cancer. We sought to assess survival outcomes after surgery as part of a multimodality treatment regimen for these patients.

Methods

Patients with cT3/T4N2M0 NSCLC who received surgery (S) as part of a multimodality approach and patients receiving multimodality treatment without surgery (chemoradiation [CRT] or systemic therapy only) were identified in the National Cancer Database (2010–2019). We evaluated factors associated with the receipt of S (logistic regression). After propensity matching, we estimated the overall survival (OS) of patients who received S and compared with those who received CRT (Kaplan-Meier and Cox regression).

Results

A total of 44,756 patients were identified, of whom 3928 (8.8%) underwent S, 29,798 (66.6%) CRT, and 11,030 (24.6%) systemic therapy only. Fewer comorbidities (Charlson-Deyo index 0 or 1, adjusted OR [aOR]: 1.22, 95% confidence interval [CI]: 1.05–1.42), treatment at an academic facility (aOR: 1.70, 95% CI: 1.52–1.89), private insurance (aOR: 2.44, 95% CI: 1.61–3.69), adenocarcinoma histology (aOR: 1.48, 95% CI: 1.22–1.79), and clinical T3 stage (<7 cm, aOR: 1.70, 95% CI: 1.53–1.89) were associated with S. In well-balanced, propensity-matched cohorts, patients selected for S had better OS compared with those who underwent CRT (hazard ratio 0.59, 95% CI: 0.56–0.63, p < 0.001) (median OS 49.7 versus 25.0 mo).

Conclusions

In this retrospective cohort analysis, patients with cT3/4N2, stage IIIB NSCLC who underwent surgical resection had better OS compared with those patients treated with CRT. Careful patient selection is undoubtedly critical, but stage IIIB designation alone should not exclude patients from surgical consideration.

Abstract Image

Abstract Image

Abstract Image

cT3/4N2M0 iii期非小细胞肺癌的手术治疗是时候重新定义可切除性了吗?
化疗后的durvalumab被认为是局部晚期NSCLC患者的标准方法。随着围手术期和新辅助方法的改进,对精心挑选的cT3/4N2期IIIB癌症患者进行手术治疗的兴趣重新燃起。我们试图评估这些患者手术后的生存结果,作为多模式治疗方案的一部分。方法:在国家癌症数据库(2010-2019)中确定了接受手术(S)作为多模式方法一部分的cT3/T4N2M0 NSCLC患者和接受多模式非手术治疗(放化疗[CRT]或仅全身治疗)的患者。我们评估了与接收S相关的因素(逻辑回归)。倾向匹配后,我们估计了接受S治疗的患者的总生存率(OS),并与接受CRT治疗的患者进行了比较(Kaplan-Meier和Cox回归)。结果:共确定44,756例患者,其中3928例(8.8%)接受S, 29,798例(66.6%)接受CRT, 11,030例(24.6%)接受全身治疗。合共病较少(Charlson-Deyo指数0或1,校正or [aOR]: 1.22, 95%可信区间[CI]: 1.05-1.42),在学术机构接受治疗(aOR: 1.70, 95% CI: 1.52-1.89),私人保险(aOR: 2.44, 95% CI: 1.61-3.69),腺癌组织学(aOR: 1.48, 95% CI: 1.22-1.79),临床T3分期(p < 0.001)(中位OS 49.7 vs 25.0个月)。结论:在这项回顾性队列分析中,cT3/4N2, IIIB期NSCLC患者接受手术切除的OS比接受CRT治疗的患者更好。谨慎的患者选择无疑是至关重要的,但仅为IIIB期不应排除患者的手术考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信